NASDAQ$STAA
STAAR Surgical Company · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
STAAR Surgical's Q3 2022 net sales increased by 30% year-over-year, driven by strong ICL sales and unit growth, despite currency headwinds and macroeconomic challenges in Europe.
STAAR Surgical Company reported net sales of $76.0 million for the third quarter of 2022, a 30% increase compared to the prior year quarter. ICL sales increased by 33% and ICL unit growth was 40%. Net income was $10.3 million, or $0.21 per diluted share, compared to $6.0 million, or $0.12 per diluted share, for the prior year quarter.
- Net sales increased by 30% to $76.0 million, with constant currency net sales up 37% from the prior year quarter.
- ICL sales grew by 33% to $72.0 million, with constant currency ICL sales up 39% from the prior year quarter.
- ICL unit growth was up 40% from the prior year quarter.
- Net income was $0.21 per share, compared to $0.12 per share in the prior year quarter.
Headline financials
Revenue & EPS history
STAAR Surgical · Revenue · Quarterly
$76M
Forward guidance
STAAR Surgical anticipates total net sales of approximately $285 million for fiscal 2022, which represents $300 million adjusted for constant currency. The fiscal 2022 outlook includes ICL sales of approximately $272 million, representing approximately 28% year over year growth, and Other Products sales of approximately $13 million. For fiscal 2023, the company expects to achieve approximately 30% ICL sales growth, year over year, to approximately $355 million in total company net sales which contemplates limited sales from Other Products.
Tailwinds
- Significant growth opportunities with premium EVO products
- Strong EVO ICL unit growth in APAC and accelerating growth in the U.S.
- Global ICL unit growth was up 40% year over year
- Expect EVO lenses to capture more than 25% of the estimated 1.2 million annual refractive procedures in China by the end of 2022
- Focus on large growth opportunities in the U.S. and Asia in 2023
Headwinds
- Tighter COVID restrictions in China resulting in expected delayed demand in the fourth quarter
- Ongoing headwinds in Europe
- Weakness in the Yen and Euro
- Lower Other Products sales
- Increasing supply chain challenges affecting the Other Products business
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+2.4%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+3.5%
Avg return
30 days after
50%
30 / 60 earnings
Positive
+29.0%
Q1 2018
Best reaction
-24.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | +14.5% | +0.6% | |
| Q4 2025 | -1.4% | -3.2% | +6.8% | |
| Q3 2025 | -0.3% | -4.9% | -0.2% | |
| Q1 2025 | +0.2% | -2.3% | -8.1% | |
| Q4 2024 | -24.7% | -29.8% | -22.1% | |
| Q3 2024 | -4.3% | -3.8% | -3.9% | |
| Q2 2024 | +6.5% | +1.7% | -17.9% | |
| Q1 2024 | -10.8% | -7.9% | -12.0% | |
| Q4 2023 | +6.6% | +8.6% | +22.9% | |
| Q3 2023 | -13.9% | -17.5% | -21.1% | |
| Q2 2023 | -10.5% | -11.6% | -18.4% | |
| Q1 2023 | -5.8% | -1.5% | -15.9% | |
| Q4 2022 | -12.7% | -18.4% | -9.6% | |
| Q3 2022 | -18.9% | -20.0% | -14.1% | |
| Q2 2022 | +23.1% | +26.6% | +16.8% | |
| Q1 2022 | +1.9% | -9.3% | +7.6% | |
| Q4 2021 | +13.1% | +20.4% | +10.7% | |
| Q3 2021 | -1.5% | -1.3% | -24.8% | |
| Q2 2021 | +21.3% | +19.4% | +22.4% | |
| Q1 2021 | +8.6% | -8.6% | +12.6% | |
| Q4 2020 | -4.3% | -4.1% | -9.7% | |
| Q3 2020 | +2.4% | +14.8% | +7.0% | |
| Q2 2020 | -6.8% | -14.2% | -16.7% | |
| Q1 2020 | -0.5% | +3.8% | +14.8% | |
| Q4 2019 | +2.0% | +4.1% | +1.9% | |
| Q3 2019 | +14.6% | +22.1% | +28.8% | |
| Q2 2019 | +14.9% | +5.9% | -0.6% | |
| Q1 2019 | -13.3% | -16.8% | -28.7% | |
| Q4 2018 | -0.6% | -1.2% | +2.7% | |
| Q3 2018 | +10.6% | +13.9% | -1.2% | |
| Q2 2018 | +25.6% | +29.3% | +54.6% | |
| Q1 2018 | +29.0% | +38.1% | +84.8% | |
| Q4 2017 | -9.1% | -8.2% | -7.2% | |
| Q3 2017 | +12.0% | +10.5% | +17.0% | |
| Q2 2017 | -1.4% | -3.3% | +11.6% | |
| Q1 2017 | -2.9% | -3.3% | -10.0% | |
| Q4 2016 | +1.5% | -2.4% | -4.4% | |
| Q3 2016 | +9.8% | +11.6% | +28.0% | |
| Q2 2016 | +19.9% | +21.5% | +30.4% | |
| Q1 2016 | -22.4% | — | — | |
| Q4 2015 | +17.1% | — | — | |
| Q3 2015 | +13.0% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q4 2013 | +10.1% | — | — | |
| Q3 2013 | -3.6% | — | — | |
| Q2 2013 | +18.6% | — | — | |
| Q1 2013 | +20.8% | — | — | |
| Q4 2012 | -5.6% | — | — | |
| Q3 2012 | +7.5% | — | — | |
| Q2 2012 | +26.3% | — | — | |
| Q1 2011 | -10.1% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q1 2009 | -0.8% | — | — | |
| Q3 2010 | +7.7% | — | — | |
| Q3 2011 | +7.7% | — | — | |
| Q4 2010 | -6.7% | — | — | |
| Q2 2010 | -6.7% | — | — | |
| Q2 2011 | -6.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro